Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Brief description of study
An Open-Label, Multicenter, First-in-Human, Dose-Escalation Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Metastatic Solid Tumors,cancer,Sarcomas
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male and Female Age 18 or older Metastatic Solid Tumors and/or Sarcomas
Updated on
09 Mar 2024.
Study ID: 849673
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
